Quantus

Alvotech

ALVO-US · Nasdaq
$4.12+15.41%
2026-07-31 close

Alvotech — pricey right now, or cheap? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Cross
Golden Cross (5_20, 0d ago)
Moving-average alignment
No
Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p

Beat the market on 57.6% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 759 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Valuation in its own history

PER — · PBR — — own history (2020-11~) percentiles 24/100 · —/100

PER24/100
PBR—/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -5.32
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-5.32
Beneish M-Score
-0.04

Statistical manipulation-risk signal

Sloan accrual
0.41%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -48%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Balance sheetDanger

자본잠식 — 자본총계가 마이너스입니다. 부실 위험을 나타내는 사실 지표입니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 21345% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 167 of 553, share 0%.

167 / 5530%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Alvotech0%

Concentration

DistributedCR3 37.1%
HHI 642553 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
22

Value lens

P90/P10
23.8
Median P/B
3.07
Level
넓음
n
467

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
0.1%
Interest coverage
0x
Return on equity (ROE)
—

Operating margin −5pp

Operating loss
Interest coverageBase 0x adverse case -0.2x
Return on equity (ROE)Base — adverse case —

Revenue −15%

Interest coverage risk
Interest coverageBase 0x adverse case 0x
Return on equity (ROE)Base — adverse case —

Interest rate +2pp

Interest coverage risk
Interest coverageBase 0x adverse case 0x
Return on equity (ROE)Base — adverse case —

Interest coverage limit

Already below the limit by 31.2pp

Interest coverage limit at an operating margin of 31.3%

Interest expense coverage threshold

Financials at a glance

Alvotech's latest results and balance sheet. The bars track the last three periods.

📦 ETFs holding this stock

by weight · top-10 constituents basis

Passive money holding this stock ≈ $0M(lower bound — top-10 basis, not a forecast)

Factual holdings info from daily disclosures — not a recommendation.

Look up another stock →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy